^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    FGFR3 K650E

    i
    Other names: FGFR3, ACH, CD333, CEK2, JTK4, Fibroblast growth factor receptor 3
    Entrez ID:
    2261
    Related biomarkers:
    Expression
    Mutation
    CNA
    Fusion
    Others
    4ms
    NCCH2006/MK010 Trial (FORTUNE Trial) (clinicaltrials.gov)
    P2, N=46, Active, not recruiting, National Cancer Center, Japan | Recruiting --> Active, not recruiting
    Enrollment closed • Metastases
    |
    EGFR (Epidermal growth factor receptor) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • NRAS (Neuroblastoma RAS viral oncogene homolog) • FGFR2 (Fibroblast growth factor receptor 2) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • FGFR4 (Fibroblast growth factor receptor 4) • NTRK (Neurotrophic receptor tyrosine kinase)
    |
    EGFR mutation • BRAF mutation • NRAS mutation • BRAF V600 • FGFR1 amplification • FGFR2 mutation • FGFR2 fusion • FGFR mutation • FGFR2 N549K • FGFR1 fusion • FGFR3 fusion • FGFR2 P253R • FGFR2 K310R • FGFR3 Y375C • FGFR2 C382R • FGFR2 N549D • FGFR2 N549H • FGFR2 S252W • FGFR2 Y375C • FGFR3 G380R • FGFR3 K650E • FGFR2 W290C
    |
    tasurgratinib (E7090)
    12ms
    Infigratinib in Recurrent High-Grade Glioma Patients (clinicaltrials.gov)
    P1, N=7, Terminated, Nader Sanai | N=20 --> 7 | Trial completion date: Jul 2023 --> Apr 2023 | Active, not recruiting --> Terminated; Study drug no longer available.
    Enrollment change • Trial completion date • Trial termination
    |
    TACC3 (Transforming acidic coiled-coil containing protein 3) • CASP3 (Caspase 3)
    |
    FGFR3 mutation • FGFR3 K650E
    |
    Truseltiq (infigratinib)
    1year
    Infigratinib in Recurrent High-Grade Glioma Patients (clinicaltrials.gov)
    P1, N=20, Active, not recruiting, Nader Sanai | Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2022 --> Mar 2023
    Enrollment closed • Trial primary completion date
    |
    TACC3 (Transforming acidic coiled-coil containing protein 3) • CASP3 (Caspase 3)
    |
    FGFR3 mutation • FGFR3 K650E
    |
    Truseltiq (infigratinib)
    over1year
    PROOF 302: Study of Oral Infigratinib for the Adjuvant Treatment of Subjects With Invasive Urothelial Carcinoma With Susceptible FGFR3 Genetic Alterations (clinicaltrials.gov)
    P3; N=218 --> 39 | Trial completion date: Jan 2025 --> Jan 2023 | Active, not recruiting --> Terminated | Trial primary completion date: Jan 2024 --> Jan 2023; The sponsor has decided to close the study due to the discontinuation of infigratinib development. The discontinuation of the study was not due to safety reasons.
    Trial completion date • Trial primary completion date • Enrollment change • Trial termination
    |
    FGFR3 mutation • FGFR3 S249C • FGFR3 Y373C • FGFR3 fusion • FGFR3 G370C • FGFR3 R248C • FGFR3 K650E
    |
    FoundationOne® CDx
    |
    Truseltiq (infigratinib)
    over1year
    PROOF 302: Study of Oral Infigratinib for the Adjuvant Treatment of Subjects With Invasive Urothelial Carcinoma With Susceptible FGFR3 Genetic Alterations (clinicaltrials.gov)
    P3; Recruiting --> Active, not recruiting
    Enrollment closed
    |
    FGFR3 mutation • FGFR3 S249C • FGFR3 Y373C • FGFR3 fusion • FGFR3 G370C • FGFR3 R248C • FGFR3 K650E
    |
    FoundationOne® CDx
    |
    Truseltiq (infigratinib)
    almost2years
    Infigratinib in Patients with Recurrent Gliomas and FGFR Alterations: A Multicenter Phase II Study. (PubMed, Clin Cancer Res)
    FGFR inhibitor monotherapy with infigratinib had limited efficacy in a population of patients with recurrent gliomas and different FGFR genetic alterations, but durable disease control lasting more than 1 year was observed in patients with tumors harboring FGFR1 or FGFR3 point mutations or FGFR3‑TACC3 fusions. A follow-up study with refined biomarker inclusion criteria and centralized FGFR testing is warranted.
    P2 data • Journal
    |
    FGFR3 (Fibroblast growth factor receptor 3) • FGFR (Fibroblast Growth Factor Receptor) • TACC3 (Transforming acidic coiled-coil containing protein 3)
    |
    FGFR3-TACC3 fusion • FGFR3 mutation • FGFR1 fusion • FGFR3 fusion • FGFR3 K650E
    |
    Truseltiq (infigratinib)